The current situation of cancer morbidity and mortality in the light of the National Cancer Registry, Hungary.
Prostate ; — Molecular pathology of prostate cancer. Molecular subtypes and perspectives of targeted therapies in prostate cancer. Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer.
Integrative clinical genomics of advanced prostate cancer. Cell ; — Germline and somatic mutations in prostate cancer for the clinician.
MENU Body size and prostate cancer risk Prostate cancer is the most common cancer in men in Europe and the second most frequently diagnosed cancer in men worldwide. Body size and prostate cancer risk.
J Natl Compr Canc Netw. Germline genetic testing in prostate cancer — further enrichment in variant histologies? Oncoscience ; 5: 62— Inherited DNA-repair gene mutations in men with metastatic prostate cancer.
N Engl J Med. Eur Urol. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
J Clin Oncol. J Clin Oncol ; — Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer ; — Medical treatment options in BRCA-associated cancers.
Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency. Prostate Cancer.
Version 2. Mutations in BRCA2 and taxane resistance in prostate cancer. Sci Rep.
Download kB Előnézet Magyar nyelvű absztrakt A prosztatarák prostate cancer, PC a világ második leggyakoribb daganata, incidenciája minden ipari országban emelkedik. A stádiumtól függően a lokális PC kezelése során műtét, sugárterápia és hormonterápia jöhet szóba.